On October 27, 2020, Glaucoma Research Foundation presented the 2020 Weston Lecture featuring a talk by world-renowned Harvard Medical School genetics researcher and best-selling author David Sinclair, PhD, AO discussing longevity research and glaucoma.
Seeing the Future: Longevity Research and Glaucoma on Vimeo https://vimeo.com/475288183?embedded=true&source=vimeo_logo&owner=687073 |
Dr. David Sinclair: The Biology of Slowing & Reversing Aging | Episode 5 https://podcasts.apple.com/us/podcast/huberman-lab/id1545953110
Dr. David Sinclair, tenured Professor of Genetics at Harvard Medical School and an expert researcher in the field of longevity. author of the book Lifespan: Why We Age & Why We Don't Have To, and the host of the Lifespan Podcast, which launches January 5, 2022. In this interview, we discuss the cellular and molecular mechanisms of aging and what we all can do
|
|
BREAKTHROUGH: Scientists Reverse Blindness [CRISPR Technology] -
www.youtube.com/watch?v=rbVvu_104Pg Leber congenital amaurosis 03:28 Injecting crispr therapy straight into the eyeballs of the visually impaired the aim was to directly correct genetic defects, the results was vastly improved vision from most of the volunteers even allowing some to see color for the first time. |
Video:
My experience with Corneal Cross Linking Procedure, here’s what to expect. https://www.youtube.com/watch?v=5kZ3qdxY_Lw Keratoconus and Corneal Cross-Linking Treatmenthttps://www.youtube.com/watch?v=GefC7fBCZl4
In general histopathology of keratoconus?
Breakdown of the tiny collagen fibers of the cornea |
Cornea cross linking procedure, due to Keratoconus
What is Keratoconus? > Corneal ectasia > A thinning disorder of the cornea > Typically located centrally and inferiorly > Causes the cornea to protrude and bulge forward > Causes progressive decrease in vision secondary to irregular Astigmatism or corneal scarring Features of keratoconus? > Non-inflammatory > Progressive - Onset as early puberty progress until 40-45 > Bilateral - most of the time one eye progresses at a faster rate than the other eye > Irregular astigmatism is one of the earliest signs Signs of keratoconus > Frequently spectacle Rx changes > Deceasing near and distance vision > Monócula diploma(seen 2 imágenes)and ghost imagen Conditions associate with keratoconus Atopic dermatitis Retinitis pigmentosa Down's syndrome The thinning and protrusion of the cornea results in? > Myopia > Irregular astigmatism |
Anglia Ruskin University
Working towards a sustainable future. At Anglia Ruskin University we're contributing to the UN's Sustainable Development Goals - and we're delighted our work on health, well-being and reduced inequalities has been recognised by THE Impact Rankings.
|
Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. In 2020, an estimated 43·3 million people were blind, 55% being female (55% F) 295 moderate and severe vision impairment, (55% F) 258 mild vision impairment, (55% F) 510 visual impairment from uncorrected presbyopia, (55% F) By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind 474 million (428 to 518) moderate and severe vision impairment, 360 million (322 to 400) mild vision impairment 866 million (629 to 1150) will have uncorrected presbyopia Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study Volume 9, Issue 2, February 2021, Pages e130-e143 https://www.sciencedirect.com/science/article/pii/S2214109X20304253 |
LOSS of EYE Sight Genetics, Luxturna
IRDs: Progressive deterioration of Rod or Cones depending upon the disease
RPE65 is one of more than 260 genes that could be responsible for a patients IRD
RPE cells are essential for the critical process that converts light into electrical impulses sent to the brain to create sight
Mutations in the RPE gene lead to vision loss due to the "loss of function" or "death" of the RPE cells and eventual degeneration of the photo receptors
AMD: Age Related Macular Degeneration - IDYOURIRD program is not for the diagnosis of patients with, or suspected of having, AMD. There appears to be both a genetic component (people with a family history are at higher risk) and environmental component (smoking may double the risk) to AMD
SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness and are caused by inherited genetic changes."
IRDs: Progressive deterioration of Rod or Cones depending upon the disease
RPE65 is one of more than 260 genes that could be responsible for a patients IRD
RPE cells are essential for the critical process that converts light into electrical impulses sent to the brain to create sight
Mutations in the RPE gene lead to vision loss due to the "loss of function" or "death" of the RPE cells and eventual degeneration of the photo receptors
AMD: Age Related Macular Degeneration - IDYOURIRD program is not for the diagnosis of patients with, or suspected of having, AMD. There appears to be both a genetic component (people with a family history are at higher risk) and environmental component (smoking may double the risk) to AMD
SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness and are caused by inherited genetic changes."
Half of the World's Population Will be Shortsighted Within 30 years.
1.Childhood blindness 2.Blindness prevention programmes: past, present, and future 3. Changing challenges in the control of blindness in children 4.The magnitude and cost of global blindness: an increasing problem that can be alleviated Between 1975 and 1995 the World Health Organization (WHO) reported an increase in the number of cases of blindness around the world from 28 to 45 million (current estimates can be found at http://www. who.int/pbd/pbl/pbl_home.htm).1 Demographic projections suggest that the world will become an older and more populated place over the next 20 years.2 If current age-specific blindness prevalence rates were to persist, the combination of population growth and increased longevity would lead to a rapid increase in the global number of cases of blindness. This could have serious economic consequences. The WHO, in partnership with the International Agency for the Prevention of Blindness launched the “VISION 2020—right to sight” initiative in 1999. The goal is the elimination of avoidable blindness due to five diseases: cataract, trachoma, onchocerciasis, vitamin A deficiency, and refractive errors. Video: Healthy eyes – new therapies maintain sight | DW Documentary https://www.youtube.com/watch?v=g82OtWou3tI Sept. 28, 2021 It has now been 24 days since millions of Ontarians have had access to primary eye care services. A real commitment from the Ontario Government to either cost recovery or ensuring Ontario optometrists are no longer the lowest funded in the country is all that is required to resume talks. Please visit www.saveeyecare.ca today. OAO President Dr. Sheldon Salaba joins a concerned patient on CP24 Toronto's Breaking News to discuss: https://bit.ly/39yC2WG #SaveEyeCare |
BUT THEN COVID HAPPENED (children confined to peering into a screen for hours every day)
Eye conditions are on the rise. From cataracts to near-sightedness and macular degeneration — millions of people worldwide suffer from poor vision. Young people are increasingly affected -- around 217 million people are visually impaired, and 36 million are blind worldwide. Nearsightedness is on the rise, sunlight is the only way to treat nearsightedness and preserve vision. The longer you go to school, the more near-sighted you become. In Taiwan, for example, myopia has reached epidemic proportions. Up to 90 percent of schoolchildren in major cities are nearsighted. What many don't realize is that if myopia remains untreated, it can even lead to blindness. |
OrCam MyEye.Increased Independence for the Blind and Visually ImpairedRevolutionary wearable device that can instantly read text from any surface, recognize faces and identify products. And now with the revolutionary Smart Reading! |
|
Link:
https://www.youtube.com/watch?v=c-PPJ5ZMLr0&feature=emb_logo OrCam MyEye: Life Changing Device To Help Blind And Visually Impaired People Live Independent Lives https://www.youtube.com/watch?v=c-PPJ5ZMLr0&feature=emb_logo |
EYE DISEASES
Corneal Dystrophy
(hazy vision which clears up as the day goes on.) Fuchs’ Dystrophy: When Is a Corneal Transplant Needed? https://www.youtube.com/watch?v=w2f2v-oC250 |
Age-related macular degeneration masqueraders: From the obvious to the obscure
Manuel Paez-Escamilla, et al., Survey of Ophthalmology, VOLUME 66, ISSUE 2, P153-182, MARCH 01, 2021 https://www.surveyophthalmol.com/article/S0039-6257(20)30128-4/fulltext Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide with increasing prevalence owing to increased life expectancy. Intravitreal injections of antivascular endothelial growth factor agents are commonly used in exudative AMD and oral antioxidant medication for nonexudative AMD; however, many disorders mimic exudative and nonexudative AMD, and misdiagnosis can seriously affect the management of these patients. We summarize the demographics and clinical and imaging characteristics of each of the conditions that masquerade as AMD. As some of the conditions have features of AMD, a short update on the classical features of AMD is also included. |
Macular Degeneration
Serum vitamin D and age-related macular degeneration: Systematic review and meta-analysis
André Ferreira, et al., Survey of Ophthalmology. Published online: August 04, 2020 p183-197
Causes of macular degeneration
|
Risk Factors
|
Prevention
|
|
|
17:00
this is the story of a revolutionary treatment for AMD Age-Related Macular Degeneration a severely disabling eye disease that can lead to blindness millions of patients are affected worldwide it's also the story of the competition between two equally effective drugs one costing 40 times more than the other until 2005 there was no effective treatment and many patients lost their sight , then came a new drug that significantly slows the progression of the disease a liquid injected directly into the eye. $50 Avastin vs. $2,000 LUCENTIS Big Pharma - How much power do drug companies have? | DW Documentary www.youtube.com/watch?v=-z_W3yRA9I8&t=37s |
|
In Sight:
|
Julia Levy(born 1934) Canadian Pathologist. Pioneer in the field of photodynamic therapy. en.wikipedia.org/wiki/Julia_Levy
She has perfected a chemotherapeutic drug that, unlike most chemotherapy drugs, is activated only when it is exposed to light. After administering the light-sensitive biochemical agent, a thin fiber-optic cable is threaded into the patient's body and directed to the exact spot on the lung, liver, pancreas, or other organ where the tumor is growing. Laser light is then beamed through the fiber-optic cable to the cancer site. When the laser hits the spot of the organ or tissue where the cancer is to be found, it activates the light-sensitive biochemical drug, which then attacks the cancer at only that one place. In this way, the treatment does not weaken the patient by attacking healthy cells like other broad-based chemical therapy treatments. Levy has extended her light-sensitive biochemical approach to treatments of arthritis, AIDS, and Age-related vision loss. Ethics: When we were setting up our our phase three trial for for the macular degeneration, the treatment worked really quite well - it didn't do any damage - it certainly dried up the bleeding in the eye = patients didn't lose vision |
Clinical Trials to Begin in 2020 on Glaucoma
|
Dr. Sinclair explains that at least in mice, researchers know that they can positively improve vision the cells that were old began to wake up they begin to
remember that they are a photoreceptor cells and not a skin cell. They are measurably younger parts of their genome that are meant to be on are turned on and the parts that are meant to be off are coiled up, and even if this is true just for mice it really is amazing. We find that with our reprogramming we can make the nerves be just like a newborn baby they grow back and then we also tested on glaucoma pressure in the eye we increased pressure in the mouse's eye and they lose their largely their eyesight and we can recover that and then we also a test old mice that don't see very well and we also seem to improve their eyesight almost back to normal. I don't think we'll be going to nursing homes any time soon but what we are doing is running a clinical trial on this and so we're looking to do that in early 2020. |
The clinical trial will be on people with glaucoma or various eye issues. The plan is glaucoma first but it could work for other damaged retinas as well even broken spinal cords what we're thinking of trying the ability to turn on or off specific parts of the genome is a very interesting proposition we can turn off parts of our genes which may cause genetic diseases. Source: Reversing Ageing: New Studies Show it Can be Done https://www.youtube.com/watch?v=XlFl0jDg0Jg&t=14s
1. www.mayo.edu/research/clinical-trials/diseases-conditions/glaucoma
2. www.glaucoma.org/research/clinical-trials.php
1. www.mayo.edu/research/clinical-trials/diseases-conditions/glaucoma
2. www.glaucoma.org/research/clinical-trials.php
Etiology
Reactive Arthritis has been identified in people with a particular genetic type called HLA-B27. They have an increased chance of developing the syndrome - about 80% of people with reactive arthritis carry this gene. Chlamydia trachomatis is the most commonly associated infection, although Neisseria gonorrhoea, salmonella, shigella, and campylobacter have all been associated Image: Reactive arthritis - uveitis Source: 1. Mycoplasma Infections, https://www.slideshare.net/doctorrao/mycoplasma 2. Increased risk of rheumatoid arthritis (RA) among patients with Mycoplasma pneumonia (MP): A nationwide population-based cohort study in Taiwan, Kuo-An Chu, Weishan Chen, Chung Y. Hsu, et al. Published: January 14, 2019, https://doi.org/10.1371/journal.pone.0210750 This cohort study demonstrated that patients with MP had a higher risk of developing RA, especially in the first 2 years, in those aged younger than 19 and over 65. |
Jobs for the Blind & Visually Impaired in 2021
15 Great Jobs for Blind People: How to Succeed With a Visual Impairment
By Publisher | Last Updated October 28, 2020 https://www.trade-schools.net/articles/jobs-for-blind-people |
|